Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2079PDF: 1663HTML: 366 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
2866PDF: 1354HTML: 3564Untitled: 191Untitled: 199Untitled: 175 -
PROLIFERATION AND APOPTOSIS OF B-CELL LYMPHOMA CELLS UNDER TARGETED REGULATION OF FOXO3 BY miR-155 miR-155, FOXO3, B-cell lymphoma, proliferation, apoptosis, clinical characteristics
755PDF: 80HTML: 134 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
462PDF: 239HTML: 77 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1023PDF: 1147Suppl. Files: 569HTML: 79 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1176PDF: 1058HTML: 190 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1349HTML: 386PDF: 812 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3737PDF: 1645HTML: 11555Figures Haase: 193 -
INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
1937PDF: 708HTML: 678Table1: patient's characteristics: 153Table 2: profile of each patient: 178 -
PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
3287PDF: 1951HTML: 7471 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2437HTML: 266PDF: 862 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9011PDF: 6038HTML: 87935Fig.1b: 180Fig.1c: 184Fig.2a: 173Fig.2b: 172Fig.4: 186Fig.2c: 180Fig.3: 179Tab.1: 224Tab.2: 205Tab.3: 186Tab.4: 220Fig1a: 178 -
EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN
3505PDF: 1172HTML: 4995Incidence age-standardized rates for HL across the Mediterranean basin: 197 -
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3232PDF: 1706HTML: 1080 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2563PDF: 797HTML: 5204 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3564PDF: 874HTML: 6708 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1504PDF: 930HTML: 218 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3516PDF: 2392HTML: 1451 -
SOLITARY PLASMACYTOMA
3821PDF: 2167HTML: 1215fIGURES 1,2: 209 -
HEPARIN-BINDING PROTEIN AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF INFECTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS Heparin-binding protein in adult patients
2147PDF: 979HTML: 142Suppl. Files: 507 -
TYROSINE KINASE INHIBITORS AND PREGNANCY
3510PDF: 1623HTML: 2670 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2147PDF: 1570HTML: 260 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
3032PDF: 870HTML: 7161Kost Fig1: 178Kost Fig 2: 175Kost Fig3: 171Kost Fig 4: 185Kost Fig5: 183Kost fig 6: 169 -
-
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2429PDF: 780HTML: 1731 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
3905PDF: 1484HTML: 9184Untitled: 273Untitled: 176Untitled: 163Untitled: 160Untitled: 176Untitled: 332 -
-
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2735PDF: 1114HTML: 3277 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
3982PDF: 1040HTML: 3579Untitled: 174Cneo. Fig.1: 111Untitled: 102Untitled: 125Untitled: 129 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2783PDF: 1002HTML: 5513







